• Browse
• Meine Registrierung (Login)
• Registrierung (frei)

Pharmaceutical News

• Architectural Code Of Caffeine's Main Target In The Body Finally Cracked
  Sun, 05 October 2008
  Many receptor models used in drug design may not be useful after all It may very well be that models used for the design of new drugs have to be regarded as impractical. This is the sobering though important conclusion of the work of two Leiden University scientists published in Science this week. The editorial board of t ...
• BioMS Medical's Phase III U.S. Multiple Sclerosis Trial Receives Positive Safety Review ...
  Sun, 05 October 2008
  BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), announced that the independent Data Safety Monitoring Board (DSMB) for the Company's U.S. pivotal phase III MAESTRO-03 trial of dirucotide (MBP8298) in patients with secondary progressive MS has completed ...
• BIPAI Opens New Children's AIDS Center In Uganda
  Sun, 05 October 2008
  The Baylor International Pediatric AIDS Initiative opened a state-of-the-art HIV/AIDS Children's Center of Excellence on the campus of Mulago Hospital in Kampala, Uganda. Baylor College of Medicine, Texas Children's Hospital, the Bristol-Myers Squibb Foundation, Mulago Hospital and the Republic of Uganda all joined forces ...
• GSK Update On FDA Review Of Promacta (eltrombopag)
  Sun, 05 October 2008
  GlaxoSmithKline announced that the United States Food and Drug Administration (FDA)continues to review the new drug application for Promacta (eltrombopag) beyond the September 19, 2008 action date. GSK continues to work closely with the FDA towards the approval of Promacta in order to provide physicians and chronic immune ( ...
• Genentech Issues Dear Healthcare Provider Letter Regarding A Reported Case Of PML In A R ...
  Sun, 05 October 2008
  Genentech, Inc. (NYSE: DNA) announced that the company has issued a Dear Healthcare Provider letter to inform potential prescribers of a case of progressive multifocal leukoencephalopathy (PML) in a 70-year old patient who had received Raptiva (efalizumab) for more than four years for treatment of chronic plaque psoriasis. T ...
• DeCODE Files IND For DG071, A Novel PDE4 Modulator Being Developed For Alzheimer's And O ...
  Sun, 05 October 2008
  deCODE genetics (Nasdaq: DCGN) announced the filing of an investigational new drug (IND) application for DG071, the company's novel small-molecule modulator of phosphodiesterase 4 (PDE4), with the US Food and Drug Administration (FDA).
• District Court Affirms Patent Infringement Rulings And Finds That Amgen Is Entitled To A ...
  Sat, 04 October 2008
  Amgen (NASDAQ:AMGN) announced today that the United States (U.S.) District Court in Boston issued its written decision upholding the prior jury verdict and court rulings regarding the infringement, validity and enforceability of 10 claims of four of Amgen's erythropoietin (EPO) patents. The Court also ruled that Amgen is ent ...
• Biotechnology Industry Organization Lauds Senate Passage Of Strengthened Two-Year R&D Cr ...
  Sat, 04 October 2008
  Urges House to Pass Economic Stabilization Package, to Bolster Investor Confidence and Hasten Therapeutic Development The Biotechnology Industry Organization (BIO) today lauded U.S. Senate passage of a 2-year extension of the federal research and development (R&D) tax credit and urged the House to pass the package when it ...
• University Of Minnesota Task Force Seeks Greater Transparency In Faculty Conflicts Of In ...
  Sat, 04 October 2008
  A task force that examined conflicts of interest at the University of Minnesota Medical School has recommended that the university expand its disclosure policy regarding relationships between the school's faculty and the drug industry, the AP/Fargo Forum reports.
• Developing GA101, A Humanized Anti-CD20 Monoclonal Antibody With Hematological Malignanc ...
  Sat, 04 October 2008
  Genentech, Inc. (NYSE:DNA), GlycArt, a company wholly-owned by Roche, and Roche (SWX:ROG) have entered into a collaboration agreement, including a license from GlycArt to Genentech, for the joint development and commercialization of GlycArt's GA101 molecule.